^
Association details:
| Biomarker: | EWSR1-CREM fusion |
|---|---|
| Cancer: | Sarcoma |
| Drug: | Votrient (pazopanib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Case report: The activity of multi-kinase VEGF inhibitor, Pazopanib, in metastatic undifferentiated round cell sarcomas harboring EWSR1::CREM fusion: clinicopathological series of two cases and literature review
Published date:
09/27/2023
Excerpt:
A 49-year-old man with a past medical history of sarcoma...Tumoral whole transcriptome sequencing identified an EWSR1::CREM fusion...He completed 13 cycles of VIT after which he presented progression of the disease and switched to monotherapy with Pazopanib (Figure 1E). He has undergone imaging every 3 months consistent with stable disease of at least 28 months...
DOI:
https://doi.org/10.3389/fonc.2023.1215003
